Kimia Biosciences Ltd
Incorporated in 1993, Kimia Biosciences
Ltd is in the business of manufacturing
and sale pharmaceutical products[1]
- Market Cap ₹ 335 Cr.
- Current Price ₹ 70.9
- High / Low ₹ 86.8 / 35.1
- Stock P/E 34.9
- Book Value ₹ 1.68
- Dividend Yield 0.00 %
- ROCE 41.3 %
- ROE 2,912 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 47.2% CAGR over last 5 years
- Company's working capital requirements have reduced from 56.0 days to 41.6 days
Cons
- Stock is trading at 43.3 times its book value
- The company has delivered a poor sales growth of 2.27% over past five years.
- Company has a low return on equity of -29.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 2 | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 105 | 119 | |
7 | 4 | 4 | 2 | 74 | 88 | 102 | 124 | 124 | 133 | 105 | 99 | |
Operating Profit | -0 | -2 | -3 | -1 | 2 | 6 | 4 | 8 | 1 | -5 | -0 | 20 |
OPM % | -5% | -110% | -1,779% | -56% | 3% | 6% | 4% | 6% | 0% | -4% | -0% | 17% |
0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 2 | 1 | |
Interest | 0 | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | 5 |
Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 3 |
Profit before tax | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 6 | -5 | -12 | -7 | 14 |
Tax % | -1% | 1% | 0% | -8% | -4% | -1% | -13% | 8% | -26% | -25% | -26% | 29% |
-1 | -2 | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -5 | 10 | |
EPS in Rs | -1.06 | -2.30 | -5.48 | -1.26 | 2.26 | 2.64 | 0.30 | 1.08 | -0.78 | -1.98 | -1.12 | 2.03 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 52% |
5 Years: | 2% |
3 Years: | -2% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 47% |
3 Years: | 66% |
TTM: | 281% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 28% |
1 Year: | 44% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -6% |
3 Years: | -30% |
Last Year: | 2912% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7 | 7 | 7 | 7 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 5 |
Reserves | -6 | -7 | -11 | -12 | 0 | 4 | 9 | 14 | 10 | 1 | -4 | -1 |
0 | 1 | 7 | 14 | 34 | 31 | 34 | 45 | 41 | 53 | 44 | 39 | |
3 | 4 | 1 | 3 | 22 | 29 | 38 | 43 | 54 | 63 | 56 | 57 | |
Total Liabilities | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 99 |
4 | 3 | 3 | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 32 | 31 | |
CWIP | 0 | 0 | 0 | 3 | 2 | 2 | 6 | 6 | 0 | 1 | 1 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 1 | 1 | 2 | 43 | 48 | 62 | 72 | 74 | 87 | 68 | 68 | |
Total Assets | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 99 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | -7 | 15 | 21 | |
-0 | 0 | -0 | -6 | -2 | -2 | -9 | -14 | -1 | -3 | -1 | -5 | |
-0 | -0 | 6 | 7 | 10 | 4 | 8 | 8 | -8 | 10 | -13 | -17 | |
Net Cash Flow | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 22 | 56 | 173 | 20 | 141 | 113 | 128 | 115 | 88 | 87 | 96 | |
Inventory Days | 75 | 50 | 319 | 615 | 59 | 83 | 92 | 89 | 146 | 183 | 149 | |
Days Payable | 988 | 667 | 91 | 511 | 120 | 91 | 121 | 116 | 159 | 177 | 194 | |
Cash Conversion Cycle | -891 | -560 | 401 | 124 | 80 | 105 | 100 | 88 | 76 | 93 | 51 | |
Working Capital Days | -58 | -530 | -173 | -1,358 | 70 | 83 | 94 | 98 | 78 | 79 | 47 | |
ROCE % | -25% | -127% | -188% | -10% | 10% | 16% | 9% | 16% | -2% | -12% | -4% |
Documents
Announcements
-
ANNOUNCEMENT UNDER REGULATION 30(LODR) REGARDING THE CLARIFICAION -PRICE MOVEMENT
15h - Company clarifies no undisclosed material event behind recent share price movement.
-
Clarification sought from Kimia Biosciences Ltd
15h - Exchange has sought clarification from Kimia Biosciences Ltd on July 2, 2025, with reference to Movement in Price.
-
Intimation Of Newspaper Advertisement Of Extraordinary General Meeting And E-Voting Information.
1d - Newspaper advertisement for EGM on July 22, 2025, with e-voting details published.
-
NOTICE OF EXTRA-ORDINARY GENERAL MEETING OF KIMIA BIOSCIENCES LIMITED
29 Jun - EGM on July 22, 2025 to regularize auditor and additional director appointments.
-
Intimation Of Extra-Ordinary General Meeting Scheduled To Be Held On 22 July,2025
29 Jun - EGM scheduled on July 22, 2025; remote e-voting from July 19-21; voting cut-off July 15.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Verticals:[1]
a) Active Pharmaceutical Ingredients
b) Commercial KSMs, Intermediates & Reagents
c) Upcoming CRAM, CDMO, CRO services